(Q35167433)

6 August 2017

1 reference

title

Fluoroquinolones, tuberculosis, and resistance (English)

1 reference

6 August 2017

0 references

3

William R Bishai

1 reference

6 August 2017

2

Jacques H Grosset

1 reference

6 August 2017

Amy Sarah Ginsburg

1

1 reference

6 August 2017

1 July 2003

1 reference

Lancet Infectious Diseases

6 August 2017

1 reference

6 August 2017

3

1 reference

6 August 2017

7

1 reference

6 August 2017

432-442

1 reference

Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic

6 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

An African perspective on the threat of tuberculosis and HIV/AIDS--can despair be turned to hope?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

The threat of multidrug resistance: is tuberculosis ever untreatable or uncontrollable?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Tuberculosis in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

National patterns in the treatment of urinary tract infections in women by ambulatory care physicians

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

In-vitro activities of quinolones against mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Activity of quinolones against mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Sterilizing activities of fluoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Intraphagocytic penetration of antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

In vitro antimycobacterial activity of a new quinolone, levofloxacin (DR-3355).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Inhibitory and bactericidal activities of levofloxacin against Mycobacterium tuberculosis in vitro and in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Combined effect of pyrazinamide and ofloxacin within the human macrophage

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Anti-Mycobacterium tuberculosis activities of new fluoroquinolones in combination with other antituberculous drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Activity of levofloxacin in a murine model of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

What have we learned from pharmacokinetic and pharmacodynamic theories?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Widespread use of fluoroquinolones versus emerging resistance in pneumococci

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

New uses for new and old quinolones and the challenge of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Application of fluoroquinolone pharmacodynamics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

The early bactericidal activity of ciprofloxacin in patients with pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

A multicentre study of the early bactericidal activity of anti-tuberculosis drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Prospective comparative study of ofloxacin or ethambutol for the treatment of pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Controlled trial of ciprofloxacin in short-term chemotherapy for pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Randomized controlled trial of a drug regimen that includes ciprofloxacin for the treatment of pulmonary tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clini

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Sparfloxacin in the treatment of drug resistant tuberculosis or intolerance of first line therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Comparative tolerability of the newer fluoroquinolone antibacterials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Quinolone-induced arthropathy in the neonatal mouse. Morphological analysis of articular lesions produced by pipemidic acid and ciprofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Quinolone arthropathy in animals versus children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Pregnancy outcome following gestational exposure to fluoroquinolones: a multicenter prospective controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Drug treatment for tuberculosis during pregnancy: safety considerations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Adverse neurological reactions in patients with multidrug-resistant pulmonary tuberculosis after coadministration of cycloserine and ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Asymptomatic hepatitis in persons who received alternative preventive therapy with pyrazinamide and ofloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

The role of fluoroquinolones in tuberculosis today

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Clinically significant interactions with drugs used in the treatment of tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

The clinical use of fluoroquinolones for the treatment of mycobacterial diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Treatment of multidrug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

In-vitro activity of ofloxacin against Mycobacterium tuberculosis and its clinical efficacy in multiply resistant pulmonary tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Mechanisms of action and resistance of older and newer fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Primary targets of fluoroquinolones in Streptococcus pneumoniae.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Mechanism of fluoroquinolone action

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Mechanisms of action of antimicrobials: focus on fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Fluoroquinolones: action and resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Emergence of fluoroquinolone-resistant tuberculosis in New York City.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

gyrA of ofloxacin-resistant clinical isolates of Mycobacterium tuberculosis from Hong Kong.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Fluoroquinolone resistance associated with specific gyrase mutations in clinical isolates of multidrug-resistant Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS C

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Selection of antibiotic-resistant bacterial mutants: allelic diversity among fluoroquinolone-resistant mutations.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Efflux pump of the proton antiporter family confers low-level fluoroquinolone resistance in Mycobacterium smegmatis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Resistance to quinolones in mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Involvement of an efflux system in mediating high level of fluoroquinolone resistance in Mycobacterium smegmatis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Impermeability to quinolones in gram-positive and gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Active efflux mechanisms for antimicrobial resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Trends in bacterial resistance to fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Fluoroquinolone use and fluoroquinolone resistance: is there an association?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Emerging mechanisms of fluoroquinolone resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Resistance among Streptococcus pneumoniae: Implications for drug selection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Multidrug resistance--a sign of the times.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

In vivo selection of Campylobacter isolates with high levels of fluoroquinolone resistance associated with gyrA mutations and the function of the CmeABC efflux pump

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

In-vitro susceptibility of mycobacteria to ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

The emergence of drug-resistant tuberculosis in New York City

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

The impact of human immunodeficiency virus infection on drug-resistant tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Relationship of isoniazid resistance to human immunodeficiency virus infection in patients with tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

A survey of drug-resistant Mycobacterium tuberculosis and its relationship to HIV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Tuberculosis in HIV-positive patients: cellular response and immune activation in the lung.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Oral bioavailability and pharmacokinetics of ciprofloxacin in patients with AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Failure of tuberculosis chemotherapy in a human immunodeficiency virus-infected patient

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Risk factors for rifampin mono-resistant tuberculosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Independent origin of mono-rifampin-resistant Mycobacterium tuberculosis in patients with AIDS

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Brief report: rifampin-resistant tuberculosis in a patient receiving rifabutin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Rifampin-monoresistant tuberculosis in New York City, 1993-1994.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Clinical use of the quinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Tolerability of fluoroquinolone antibiotics. Past, present and future

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

Streptococcus pneumoniae resistance to fluoroquinolones

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2803%2900671-6

7 January 2021

10.1016/S1473-3099(03)00671-6

Identifiers

DOI

1 reference

6 August 2017

1 reference

PubMed ID

12837348